{"id":23150,"date":"2025-12-11T09:25:34","date_gmt":"2025-12-11T02:25:34","guid":{"rendered":"https:\/\/b-company.jp\/?p=23150"},"modified":"2025-12-11T09:25:34","modified_gmt":"2025-12-11T02:25:34","slug":"pharmaceutical-market-in-vietnam-landscape-key-players-and-regulatory-overview","status":"publish","type":"post","link":"https:\/\/b-company.jp\/vi\/pharmaceutical-market-in-vietnam-landscape-key-players-and-regulatory-overview\/","title":{"rendered":"Th\u1ecb tr\u01b0\u1eddng d\u01b0\u1ee3c ph\u1ea9m t\u1ea1i Vi\u1ec7t Nam: T\u1ed5ng quan, c\u00e1c nh\u00e0 s\u1ea3n xu\u1ea5t ch\u00ednh v\u00e0 quy \u0111\u1ecbnh ph\u00e1p l\u00fd."},"content":{"rendered":"
<\/div>
<\/div><\/div><\/div>
<\/i><\/div>

C\u00f4ng ty nghi\u00ean c\u1ee9u th\u1ecb tr\u01b0\u1eddng c\u1ee7a Nh\u1eadt B\u1ea3n \u0111\u1ea7u ti\u00ean t\u1ea1i Vi\u1ec7t Nam t\u1eeb n\u0103m 2008. Ch\u00fang t\u00f4i cung c\u1ea5p \u0111a d\u1ea1ng nh\u1eefng d\u1ecbch v\u1ee5 bao g\u1ed3m nh\u01b0 b\u00e1o c\u00e1o ng\u00e0nh, kh\u1ea3o s\u00e1t ng\u01b0\u1eddi ti\u00eau d\u00f9ng, k\u1ebft n\u1ed1i kinh doanh.<\/em><\/p>\n

Trong chuy\u00ean m\u1ee5c \u201cB\u1ea3n tin Vi\u1ec7t Nam\u201d n\u00e0y, c\u00e1c nh\u00e0 nghi\u00ean c\u1ee9u tr\u1ebb c\u1ee7a B&Company s\u1ebd cung c\u1ea5p th\u00f4ng tin c\u1eadp nh\u1eadt v\u1ec1 xu h\u01b0\u1edbng c\u00e1c ng\u00e0nh c\u00f4ng nghi\u1ec7p, xu h\u01b0\u1edbng ti\u00eau d\u00f9ng v\u00e0 x\u00e3 h\u1ed9i Vi\u1ec7t Nam. Nh\u1eefng di\u1ec5n gi\u1ea3i v\u00e0 tri\u1ec3n v\u1ecdng trong t\u01b0\u01a1ng lai l\u00e0 \u00fd ki\u1ebfn c\u00e1 nh\u00e2n c\u1ee7a m\u1ed7i nh\u00e0 nghi\u00ean c\u1ee9u.<\/em><\/p>\n

B\u00e0i vi\u1ebft n\u00e0y \u0111\u01b0\u1ee3c vi\u1ebft b\u1eb1ng ti\u1ebfng Anh v\u00e0 b\u1ea3n d\u1ecbch t\u1ef1 \u0111\u1ed9ng \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng cho c\u00e1c phi\u00ean b\u1ea3n ng\u00f4n ng\u1eef kh\u00e1c. Vui l\u00f2ng tham kh\u1ea3o phi\u00ean b\u1ea3n ti\u1ebfng Anh \u0111\u1ec3 bi\u1ebft n\u1ed9i dung ch\u00ednh x\u00e1c. <\/em><\/p>\n<\/div>\n\t

\n\t\t
\n\t\t\t\n\t\t<\/div>\n\t<\/div>\n

Th\u1ecb tr\u01b0\u1eddng d\u01b0\u1ee3c ph\u1ea9m Vi\u1ec7t Nam l\u00e0 m\u1ed9t trong nh\u1eefng th\u1ecb tr\u01b0\u1eddng ph\u00e1t tri\u1ec3n nhanh nh\u1ea5t \u0110\u00f4ng Nam \u00c1, \u0111\u01b0\u1ee3c th\u00fac \u0111\u1ea9y b\u1edfi thu nh\u1eadp t\u0103ng, d\u00e2n s\u1ed1 gi\u00e0 h\u00f3a v\u00e0 ph\u1ea1m vi b\u1ea3o hi\u1ec3m y t\u1ebf ng\u00e0y c\u00e0ng m\u1edf r\u1ed9ng. C\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m t\u1ea1i Vi\u1ec7t Nam ho\u1ea1t \u0111\u1ed9ng trong m\u1ed9t m\u00f4i tr\u01b0\u1eddng \u0111\u01b0\u1ee3c qu\u1ea3n l\u00fd ch\u1eb7t ch\u1ebd nh\u01b0ng \u0111ang d\u1ea7n \u0111\u01b0\u1ee3c t\u1ef1 do h\u00f3a, khuy\u1ebfn kh\u00edch \u0111\u1ea7u t\u01b0 v\u00e0o s\u1ea3n xu\u1ea5t, thu\u1ed1c g\u1ed1c v\u00e0 c\u00e1c li\u1ec7u ph\u00e1p \u0111i\u1ec1u tr\u1ecb c\u00f3 gi\u00e1 tr\u1ecb cao. B\u00e0i vi\u1ebft n\u00e0y ph\u00e1c th\u1ea3o khung ph\u00e1p l\u00fd, quy m\u00f4 v\u00e0 c\u1ea5u tr\u00fac th\u1ecb tr\u01b0\u1eddng, gi\u1edbi thi\u1ec7u 10 c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m h\u00e0ng \u0111\u1ea7u t\u1ea1i Vi\u1ec7t Nam, n\u00eau b\u1eadt c\u00e1c xu h\u01b0\u1edbng g\u1ea7n \u0111\u00e2y nh\u01b0 s\u00e1p nh\u1eadp v\u00e0 mua l\u1ea1i (M&A) v\u00e0 m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng thu\u1ed1c g\u1ed1c, v\u00e0 k\u1ebft lu\u1eadn v\u1edbi nh\u1eefng h\u00e0m \u00fd th\u1ef1c ti\u1ec5n d\u00e0nh cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 n\u01b0\u1edbc ngo\u00e0i \u0111ang c\u00e2n nh\u1eafc th\u00e2m nh\u1eadp ho\u1eb7c m\u1edf r\u1ed9ng ho\u1ea1t \u0111\u1ed9ng t\u1ea1i th\u1ecb tr\u01b0\u1eddng n\u0103ng \u0111\u1ed9ng n\u00e0y.<\/p>\n

Quy \u0111\u1ecbnh<\/strong><\/h3>\n

Theo c\u00e1c cam k\u1ebft c\u1ee7a Vi\u1ec7t Nam v\u1edbi WTO v\u00e0 c\u00e1c quy \u0111\u1ecbnh hi\u1ec7n h\u00e0nh (\u0111\u01b0\u1ee3c \u0111i\u1ec1u ch\u1ec9nh b\u1edfi Lu\u1eadt D\u01b0\u1ee3c v\u00e0 Ngh\u1ecb \u0111\u1ecbnh 09\/2018\/ND-CP), c\u00e1c doanh nghi\u1ec7p d\u01b0\u1ee3c ph\u1ea9m c\u00f3 v\u1ed1n \u0111\u1ea7u t\u01b0 n\u01b0\u1edbc ngo\u00e0i (FIE) n\u00f3i chung \u0111\u01b0\u1ee3c ph\u00e9p nh\u1eadp kh\u1ea9u d\u01b0\u1ee3c ph\u1ea9m (thu\u1ed1c v\u00e0 nguy\u00ean li\u1ec7u) nh\u01b0ng b\u1ecb c\u1ea5m th\u1ef1c hi\u1ec7n quy\u1ec1n ph\u00e2n ph\u1ed1i (b\u00e1n bu\u00f4n ho\u1eb7c b\u00e1n l\u1ebb) c\u00e1c s\u1ea3n ph\u1ea9m n\u00e0y tr\u1ef1c ti\u1ebfp trong l\u00e3nh th\u1ed5 Vi\u1ec7t Nam.<\/p>\n

Ngo\u1ea1i l\u1ec7 quan tr\u1ecdng l\u00e0 \u0111\u1ed1i v\u1edbi c\u00e1c lo\u1ea1i thu\u1ed1c th\u00e0nh ph\u1ea9m do c\u00e1c doanh nghi\u1ec7p c\u00f3 v\u1ed1n \u0111\u1ea7u t\u01b0 n\u01b0\u1edbc ngo\u00e0i s\u1ea3n xu\u1ea5t trong n\u01b0\u1edbc t\u1ea1i Vi\u1ec7t Nam. Theo \u0111\u00f3, c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m n\u01b0\u1edbc ngo\u00e0i ph\u1ea3i b\u00e1n c\u00e1c s\u1ea3n ph\u1ea9m nh\u1eadp kh\u1ea9u c\u1ee7a m\u00ecnh th\u00f4ng qua c\u00e1c nh\u00e0 ph\u00e2n ph\u1ed1i s\u1ec9 ho\u1eb7c \u0111\u1ed1i t\u00e1c trong n\u01b0\u1edbc \u0111\u00e3 \u0111\u0103ng k\u00fd, nh\u1eefng \u0111\u01a1n v\u1ecb n\u00e0y sau \u0111\u00f3 s\u1ebd qu\u1ea3n l\u00fd vi\u1ec7c ph\u00e2n ph\u1ed1i \u0111\u1ebfn c\u00e1c b\u1ec7nh vi\u1ec7n (thu\u1ed1c ti\u00eam ch\u00edch) v\u00e0 nh\u00e0 thu\u1ed1c (thu\u1ed1c kh\u00f4ng k\u00ea \u0111\u01a1n).<\/p>\n

T\u1ed5ng quan th\u1ecb tr\u01b0\u1eddng<\/strong><\/h3>\n

Th\u1ecb tr\u01b0\u1eddng d\u01b0\u1ee3c ph\u1ea9m Vi\u1ec7t Nam \u0111\u01b0\u1ee3c \u0111\u1ecbnh gi\u00e1 kho\u1ea3ng 6 t\u1ef7 USD v\u00e0o n\u0103m 2023, d\u1ef1 ki\u1ebfn \u0111\u1ea1t 8,7 t\u1ef7 USD v\u00e0o n\u0103m 2028 v\u00e0 11,6 t\u1ef7 USD v\u00e0o n\u0103m 2033.[1]<\/a>Ngo\u00e0i ra, th\u1ecb tr\u01b0\u1eddng nghi\u00eang m\u1ea1nh v\u1ec1 thu\u1ed1c generic, v\u1edbi th\u1ecb ph\u1ea7n t\u0103ng t\u1eeb 58,11% n\u0103m 2023 l\u00ean 62,41% n\u0103m 2029.[2]<\/a>Trong \u0111\u00f3, c\u00e1c nh\u00e0 s\u1ea3n xu\u1ea5t trong n\u01b0\u1edbc t\u1eadp trung v\u00e0o c\u00e1c li\u1ec7u ph\u00e1p th\u00f4ng th\u01b0\u1eddng (kh\u00e1ng sinh, tim m\u1ea1ch, gi\u1ea3m \u0111au, ti\u1ec3u \u0111\u01b0\u1eddng) v\u00e0 thu\u1ed1c th\u1ea3o d\u01b0\u1ee3c truy\u1ec1n th\u1ed1ng. D\u1ef1 b\u00e1o ph\u00e2n kh\u00fac thu\u1ed1c generic s\u1ebd t\u0103ng tr\u01b0\u1edfng v\u1edbi t\u1ed1c \u0111\u1ed9 CAGR kho\u1ea3ng 9,71 t\u1ef7 USD\/3 t\u1ef7 USD t\u1eeb n\u0103m 2024 \u0111\u1ebfn n\u0103m 2029, nhanh nh\u1ea5t trong khu v\u1ef1c ASEAN.[3]<\/a>M\u1eb7c d\u00f9 th\u1ecb tr\u01b0\u1eddng d\u01b0\u1ee3c ph\u1ea9m kh\u00f4ng k\u00ea \u0111\u01a1n c\u1ee7a Vi\u1ec7t Nam v\u1eabn c\u00f2n k\u00e9m ph\u00e1t tri\u1ec3n, nh\u01b0ng d\u1ef1 ki\u1ebfn s\u1ebd t\u0103ng tr\u01b0\u1edfng nhanh ch\u00f3ng v\u00e0 m\u1edf ra nhi\u1ec1u c\u01a1 h\u1ed9i t\u0103ng tr\u01b0\u1edfng \u0111\u00e1ng k\u1ec3.[4]<\/a>.<\/p>\n

Ngo\u00e0i ra, Vi\u1ec7t Nam v\u1eabn ph\u1ee5 thu\u1ed9c r\u1ea5t nhi\u1ec1u v\u00e0o nh\u1eadp kh\u1ea9u c\u00e1c nh\u00e3n hi\u1ec7u g\u1ed1c, ch\u1ebf ph\u1ea9m sinh h\u1ecdc v\u00e0 v\u1eafc-xin. C\u1ee5 th\u1ec3, c\u00e1c m\u1eb7t h\u00e0ng nh\u1eadp kh\u1ea9u c\u00f3 gi\u00e1 tr\u1ecb cao n\u00e0y ch\u1ee7 y\u1ebfu \u0111\u1ebfn t\u1eeb c\u00e1c th\u1ecb tr\u01b0\u1eddng ph\u00e1t tri\u1ec3n, trong \u0111\u00f3 Ph\u00e1p, \u0110\u1ee9c v\u00e0 M\u1ef9 lu\u00f4n n\u1eb1m trong s\u1ed1 c\u00e1c nh\u00e0 cung c\u1ea5p thu\u1ed1c th\u00e0nh ph\u1ea9m h\u00e0ng \u0111\u1ea7u.[5]<\/a>Trong khi \u0111\u00f3, \u1ea4n \u0110\u1ed9 v\u00e0 Trung Qu\u1ed1c chi\u1ebfm \u01b0u th\u1ebf trong vi\u1ec7c cung c\u1ea5p thu\u1ed1c generic v\u00e0 c\u00e1c ho\u1ea1t ch\u1ea5t d\u01b0\u1ee3c ph\u1ea9m (API).[6]<\/a>Hi\u1ec7p \u0111\u1ecbnh EVFTA \u0111\u00e3 c\u1ee7ng c\u1ed1 h\u01a1n n\u1eefa vai tr\u00f2 c\u1ee7a EU nh\u01b0 m\u1ed9t ngu\u1ed3n cung c\u1ea5p quan tr\u1ecdng c\u00e1c lo\u1ea1i d\u01b0\u1ee3c ph\u1ea9m ch\u1ea5t l\u01b0\u1ee3ng cao v\u00e0 c\u00f3 t\u00ednh \u0111\u1ed5i m\u1edbi.<\/p>\n

Market share of imported and domestic pharmaceuticals in Vietnam <\/strong>t\u1eeb n\u0103m 2019 \u0111\u1ebfn n\u0103m 2022<\/strong><\/p>\n

\u0110\u01a1n v\u1ecb: %
\n\"Market<\/p>\n

Ngu\u1ed3n: Statista[7]<\/a><\/p>\n

V\u1ec1 c\u00e1c y\u1ebfu t\u1ed1 kinh t\u1ebf v\u0129 m\u00f4, Vi\u1ec7t Nam \u0111ang tr\u1ea3i qua s\u1ef1 chuy\u1ec3n \u0111\u1ed5i nh\u00e2n kh\u1ea9u h\u1ecdc m\u1ea1nh m\u1ebd. N\u0103m 2024, g\u1ea7n 14,2 tri\u1ec7u ng\u01b0\u1eddi (h\u01a1n 141.300.000 d\u00e2n s\u1ed1) t\u1eeb 60 tu\u1ed5i tr\u1edf l\u00ean. \u0110\u1ebfn n\u0103m 2050, con s\u1ed1 n\u00e0y d\u1ef1 ki\u1ebfn s\u1ebd t\u0103ng g\u1ea5p \u0111\u00f4i l\u00ean h\u01a1n 29 tri\u1ec7u ng\u01b0\u1eddi. D\u00e2n s\u1ed1 gi\u00e0 h\u00f3a c\u00f3 m\u1ed1i li\u00ean h\u1ec7 tr\u1ef1c ti\u1ebfp v\u1edbi g\u00e1nh n\u1eb7ng gia t\u0103ng c\u1ee7a c\u00e1c b\u1ec7nh m\u00e3n t\u00ednh kh\u00f4ng l\u00e2y nhi\u1ec5m (NCD) nh\u01b0 b\u1ec7nh tim m\u1ea1ch, ti\u1ec3u \u0111\u01b0\u1eddng v\u00e0 ung th\u01b0, \u0111\u00f2i h\u1ecfi c\u00e1c ph\u00e1c \u0111\u1ed3 \u0111i\u1ec1u tr\u1ecb d\u00e0i h\u1ea1n.1<\/sup>.<\/p>\n

Xu h\u01b0\u1edbng th\u1ecb tr\u01b0\u1eddng<\/strong><\/h3>\n

Ph\u00e2n kh\u00fac ETC (b\u1ec7nh vi\u1ec7n) v\u1eabn l\u00e0 ngu\u1ed3n gi\u00e1 tr\u1ecb ch\u1ee7 \u0111\u1ea1o v\u00e0 \u0111ang ph\u00e1t tri\u1ec3n, t\u0103ng th\u1ecb ph\u1ea7n t\u1eeb 74,61 ngh\u00ecn t\u1ef7 nh\u00e2n d\u00e2n t\u1ec7 n\u0103m 2017 l\u00ean d\u1ef1 ki\u1ebfn 76,41 ngh\u00ecn t\u1ef7 nh\u00e2n d\u00e2n t\u1ec7 v\u00e0o n\u0103m 2024. Xu h\u01b0\u1edbng n\u00e0y \u0111\u01b0\u1ee3c th\u00fac \u0111\u1ea9y b\u1edfi vi\u1ec7c ti\u00eau th\u1ee5 c\u00e1c lo\u1ea1i thu\u1ed1c chuy\u00ean khoa c\u00f3 gi\u00e1 tr\u1ecb cao. \u0110\u1ed3ng th\u1eddi, k\u00eanh b\u00e1n l\u1ebb d\u01b0\u1ee3c ph\u1ea9m v\u00e0 thu\u1ed1c kh\u00f4ng k\u00ea \u0111\u01a1n (OTC) \u0111ang tr\u1ea3i qua s\u1ef1 m\u1edf r\u1ed9ng v\u1ec1 c\u1ea5u tr\u00fac x\u00e9t v\u1ec1 ph\u1ea1m vi ph\u00e2n ph\u1ed1i, m\u1eb7c d\u00f9 th\u1ecb ph\u1ea7n gi\u00e1 tr\u1ecb gi\u1ea3m t\u1eeb 25,41 ngh\u00ecn t\u1ef7 nh\u00e2n d\u00e2n t\u1ec7 xu\u1ed1ng c\u00f2n 23,61 ngh\u00ecn t\u1ef7 nh\u00e2n d\u00e2n t\u1ec7 trong c\u00f9ng k\u1ef3. S\u1ef1 m\u1edf r\u1ed9ng n\u00e0y hi\u1ec7n \u0111ang \u0111\u01b0\u1ee3c \u0111\u00e1nh d\u1ea5u b\u1eb1ng s\u1ef1 ph\u00e1t tri\u1ec3n nhanh ch\u00f3ng c\u1ee7a c\u00e1c chu\u1ed7i nh\u00e0 thu\u1ed1c hi\u1ec7n \u0111\u1ea1i, \u0111ang chuy\u00ean nghi\u1ec7p h\u00f3a b\u1ed1i c\u1ea3nh b\u00e1n l\u1ebb, t\u1ea1o ra s\u1ef1 c\u1ea1nh tranh gay g\u1eaft trong ph\u00e2n kh\u00fac doanh s\u1ed1 OTC. Trong b\u1ed1i c\u1ea3nh b\u00e1n l\u1ebb, th\u1ecb tr\u01b0\u1eddng ng\u00e0y c\u00e0ng b\u1ecb chi ph\u1ed1i b\u1edfi ba chu\u1ed7i nh\u00e0 thu\u1ed1c l\u1edbn l\u00e0 FPT Long Ch\u00e2u, Pharmacity v\u00e0 An Khang, v\u1edbi t\u1ed5ng s\u1ed1 g\u1ea7n 3.200 c\u1eeda h\u00e0ng v\u00e0o n\u0103m 2024.[8]<\/a>Tuy nhi\u00ean, m\u00f4 h\u00ecnh ph\u00e2n t\u00e1n truy\u1ec1n th\u1ed1ng v\u1eabn c\u00f2n r\u1ea5t ph\u1ed5 bi\u1ebfn. C\u00e1c hi\u1ec7u thu\u1ed1c nh\u1ecf \u0111\u1ed9c l\u1eadp v\u1eabn chi\u1ebfm kho\u1ea3ng 851.300 USD trong t\u1ed5ng th\u1ecb tr\u01b0\u1eddng b\u00e1n l\u1ebb, bao g\u1ed3m kho\u1ea3ng 50.000 hi\u1ec7u thu\u1ed1c b\u00e1n l\u1ebb tr\u00ean to\u00e0n qu\u1ed1c.[9]<\/a>.<\/p>\n

T\u1ef7 l\u1ec7 doanh thu c\u1ee7a ETC\/OTC<\/strong><\/p>\n

\u0110\u01a1n v\u1ecb: %
\n\"Revenue<\/p>\n

Ngu\u1ed3n: Fitch Solutions[10]<\/a><\/p>\n

M\u1ed9t ch\u1ee7 \u0111\u1ec1 n\u1ed5i b\u1eadt kh\u00e1c l\u00e0 s\u00e1p nh\u1eadp v\u00e0 mua l\u1ea1i (M&A) v\u00e0 c\u00e1c li\u00ean minh chi\u1ebfn l\u01b0\u1ee3c. L\u0129nh v\u1ef1c n\u00e0y \u0111\u00e3 ch\u1ee9ng ki\u1ebfn ho\u1ea1t \u0111\u1ed9ng \u0111\u00e1ng ch\u00fa \u00fd, bao g\u1ed3m vi\u1ec7c c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 n\u01b0\u1edbc ngo\u00e0i mua c\u1ed5 ph\u1ea7n l\u1edbn h\u01a1n trong c\u00e1c nh\u00e0 s\u1ea3n xu\u1ea5t trong n\u01b0\u1edbc, c\u00e1c giao d\u1ecbch M&A l\u1edbn d\u1ef1 ki\u1ebfn s\u1ebd v\u01b0\u1ee3t qu\u00e1 5.700 t\u1ef7 \u0111\u1ed3ng v\u00e0o n\u0103m 2025, v\u00e0 vi\u1ec7c h\u00ecnh th\u00e0nh c\u00e1c li\u00ean minh d\u00e0i h\u1ea1n \u0111\u1ec3 chuy\u1ec3n giao c\u00f4ng ngh\u1ec7, ch\u1eb3ng h\u1ea1n nh\u01b0 trong s\u1ea3n xu\u1ea5t v\u1eafc-xin.[11]<\/a>V\u00e0o n\u0103m 2023, c\u00f4ng ty Dongwha Pharm c\u1ee7a H\u00e0n Qu\u1ed1c \u0111\u00e3 th\u00f4ng b\u00e1o mua l\u1ea1i 51% c\u1ed5 ph\u1ea7n c\u1ee7a Trung S\u01a1n Pharma.[12]<\/a>V\u00e0o n\u0103m 2025, T\u1eadp \u0111o\u00e0n D\u01b0\u1ee3c ph\u1ea9m Livzon (Trung Qu\u1ed1c), th\u00f4ng qua c\u00f4ng ty con thu\u1ed9c s\u1edf h\u1eefu ho\u00e0n to\u00e0n t\u1ea1i Singapore l\u00e0 Lian SGP Holding Pte. Ltd., \u0111\u00e3 c\u00f4ng b\u1ed1 k\u1ebf ho\u1ea1ch chi h\u01a1n 5.730 t\u1ef7 \u0111\u1ed3ng ti\u1ec1n m\u1eb7t \u0111\u1ec3 mua l\u1ea1i g\u1ea7n 651.000 c\u1ed5 ph\u1ea7n c\u1ee7a C\u00f4ng ty D\u01b0\u1ee3c ph\u1ea9m Imexpharm.[13]<\/a>Sau khi giao d\u1ecbch ho\u00e0n t\u1ea5t, Imexpharm s\u1ebd tr\u1edf th\u00e0nh c\u00f4ng ty con gi\u00e1n ti\u1ebfp c\u1ee7a Livzon.<\/p>\n

Ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m Vi\u1ec7t Nam \u0111ang tr\u1ea3i qua qu\u00e1 tr\u00ecnh chuy\u1ec3n \u0111\u1ed5i nhanh ch\u00f3ng h\u01b0\u1edbng t\u1edbi c\u00e1c ti\u00eau chu\u1ea9n qu\u1ed1c t\u1ebf nghi\u00eam ng\u1eb7t nh\u01b0 EU-GMP v\u00e0 Japan-GMP, v\u01b0\u1ee3t ra kh\u1ecfi s\u1ef1 ph\u1ee5 thu\u1ed9c truy\u1ec1n th\u1ed1ng v\u00e0o WHO-GMP. M\u1eb7c d\u00f9 hi\u1ec7n t\u1ea1i d\u1ef1 ki\u1ebfn ch\u1ec9 c\u00f3 ch\u01b0a \u0111\u1ebfn 101 t\u1ea5n\/3 t\u1ea5n c\u01a1 s\u1edf s\u1ea3n xu\u1ea5t trong n\u01b0\u1edbc \u0111\u1ea1t ti\u00eau chu\u1ea9n EU-GMP v\u00e0o gi\u1eefa n\u0103m 2025, nh\u01b0ng t\u1ef7 l\u1ec7 \u00e1p d\u1ee5ng \u0111ang t\u0103ng nhanh ch\u00f3ng trong s\u1ed1 c\u00e1c doanh nghi\u1ec7p h\u00e0ng \u0111\u1ea7u th\u1ecb tr\u01b0\u1eddng (v\u00ed d\u1ee5: Imexpharm, Pymepharco, DHG Pharma). Vi\u1ec7c \u0111\u1ea1t \u0111\u01b0\u1ee3c c\u00e1c ch\u1ee9ng nh\u1eadn n\u00e0y \u0111\u00f3ng vai tr\u00f2 nh\u01b0 m\u1ed9t \u201ct\u1ea5m v\u00e9 th\u00f4ng h\u00e0nh\u201d quan tr\u1ecdng cho vi\u1ec7c m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng, gi\u00fap c\u00e1c c\u00f4ng ty ti\u1ebfp c\u1eadn c\u00e1c g\u00f3i th\u1ea7u gi\u00e1 tr\u1ecb cao v\u00e0 c\u1ea1nh tranh trong c\u00e1c th\u1ecb tr\u01b0\u1eddng kh\u1eaft khe. Vi\u1ec7c n\u00e2ng cao ch\u1ea5t l\u01b0\u1ee3ng n\u00e0y c\u0169ng t\u1ea1o \u0111i\u1ec1u ki\u1ec7n thu\u1eadn l\u1ee3i cho vi\u1ec7c chuy\u1ec3n \u0111\u1ed5i s\u1ea3n xu\u1ea5t t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c generic c\u01a1 b\u1ea3n sang c\u00e1c s\u1ea3n ph\u1ea9m ph\u1ee9c t\u1ea1p, c\u00f3 bi\u00ean l\u1ee3i nhu\u1eadn cao nh\u01b0 thu\u1ed1c generic chuy\u00ean d\u1ee5ng cho c\u00e1c b\u1ec7nh kh\u00f4ng l\u00e2y nhi\u1ec5m v\u00e0 thu\u1ed1c \u0111i\u1ec1u tr\u1ecb ung th\u01b0, t\u1eeb \u0111\u00f3 c\u1ee7ng c\u1ed1 v\u1ecb th\u1ebf c\u1ee7a Vi\u1ec7t Nam nh\u01b0 m\u1ed9t trung t\u00e2m s\u1ea3n xu\u1ea5t \u0111\u00e1ng tin c\u1eady trong khu v\u1ef1c. [14]<\/a>Nh\u1eefng v\u00ed d\u1ee5 th\u00e0nh c\u00f4ng, nh\u01b0 vi\u1ec7c Imexpharm xu\u1ea5t kh\u1ea9u sang EU, ch\u1ee9ng minh r\u1eb1ng kho\u1ea3n \u0111\u1ea7u t\u01b0 chi\u1ebfn l\u01b0\u1ee3c v\u00e0o vi\u1ec7c tu\u00e2n th\u1ee7 ch\u1ea5t l\u01b0\u1ee3ng \u0111\u00e3 gi\u00fap Vi\u1ec7t Nam kh\u1eb3ng \u0111\u1ecbnh v\u1ecb th\u1ebf l\u00e0 trung t\u00e2m s\u1ea3n xu\u1ea5t v\u00e0 xu\u1ea5t kh\u1ea9u \u0111\u00e1ng tin c\u1eady trong khu v\u1ef1c.<\/p>\n

Cu\u1ed1i c\u00f9ng, s\u1ed1 h\u00f3a \u0111ang \u0111\u1ecbnh h\u00ecnh l\u1ea1i b\u1ed1i c\u1ea3nh b\u00e1n l\u1ebb. C\u00e1c chu\u1ed7i nh\u00e0 thu\u1ed1c hi\u1ec7n \u0111\u1ea1i v\u00e0 n\u1ec1n t\u1ea3ng ph\u00e2n ph\u1ed1i k\u1ef9 thu\u1eadt s\u1ed1 \u0111ang t\u0103ng c\u01b0\u1eddng ph\u1ea1m vi ph\u1ee7 s\u00f3ng b\u00e1n l\u1ebb v\u00e0 kh\u1ea3 n\u0103ng hi\u1ec3n th\u1ecb d\u1eef li\u1ec7u. H\u01a1n n\u1eefa, t\u1ed1i \u01b0u h\u00f3a k\u1ef9 thu\u1eadt s\u1ed1 gi\u00fap gi\u1ea3m chi ph\u00ed v\u1eadn h\u00e0nh, cho ph\u00e9p c\u00e1c chu\u1ed7i l\u1edbn th\u1ef1c hi\u1ec7n c\u00e1c chi\u1ebfn l\u01b0\u1ee3c \u0111\u1ecbnh gi\u00e1 v\u00e0 khuy\u1ebfn m\u00e3i m\u1ea1nh m\u1ebd \u0111\u1ec3 nhanh ch\u00f3ng gi\u00e0nh th\u1ecb ph\u1ea7n.<\/p>\n

Ng\u01b0\u1eddi ch\u01a1i ch\u00ednh<\/strong><\/h3>\n

C\u00e1c c\u00f4ng ty n\u1ed9i \u0111\u1ecba l\u1edbn nh\u1ea5t (DHG, Traphaco, Stellapharm, Imexpharm) m\u1ed7i c\u00f4ng ty \u0111\u1ea1t doanh thu thu\u1ea7n h\u00e0ng n\u0103m kho\u1ea3ng 2 ngh\u00ecn t\u1ef7 \u0111\u1ed3ng \u0111\u1ebfn g\u1ea7n 6 ngh\u00ecn t\u1ef7 \u0111\u1ed3ng. C\u00e1c t\u1eadp \u0111o\u00e0n n\u01b0\u1edbc ngo\u00e0i l\u1edbn nh\u01b0 Sanofi s\u1eed d\u1ee5ng Vi\u1ec7t Nam nh\u01b0 m\u1ed9t th\u1ecb tr\u01b0\u1eddng t\u0103ng tr\u01b0\u1edfng v\u00e0 c\u0169ng l\u00e0 c\u01a1 s\u1edf s\u1ea3n xu\u1ea5t\/xu\u1ea5t kh\u1ea9u, v\u00e0 ng\u00e0y c\u00e0ng tham gia v\u00e0o chuy\u1ec3n giao c\u00f4ng ngh\u1ec7 v\u00e0 h\u1ee3p t\u00e1c v\u1edbi c\u00e1c \u0111\u1ed1i t\u00e1c \u0111\u1ecba ph\u01b0\u01a1ng, \u0111\u1eb7c bi\u1ec7t l\u00e0 trong l\u0129nh v\u1ef1c v\u1eafc-xin v\u00e0 c\u00e1c li\u1ec7u ph\u00e1p \u0111i\u1ec1u tr\u1ecb gi\u00e1 cao. Nhi\u1ec1u c\u00f4ng ty trong n\u01b0\u1edbc chuy\u00ean v\u1ec1 thu\u1ed1c th\u1ea3o d\u01b0\u1ee3c\/thu\u1ed1c truy\u1ec1n th\u1ed1ng ho\u1eb7c thu\u1ed1c g\u1ed1c \u0111\u1ea1t ti\u00eau chu\u1ea9n EU-GMP, m\u1edf ra c\u01a1 h\u1ed9i xu\u1ea5t kh\u1ea9u v\u00e0 gia c\u00f4ng s\u1ea3n xu\u1ea5t cho c\u00e1c \u0111\u1ed1i t\u00e1c \u0111a qu\u1ed1c gia.<\/p>\n

Ngo\u00e0i ra, n\u0103m 2024 ghi nh\u1eadn kho\u1ea3ng 159 c\u00f4ng ty n\u01b0\u1edbc ngo\u00e0i \u0111\u1ea7u t\u01b0 kho\u1ea3ng 1,8 t\u1ef7 USD v\u00e0o ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m Vi\u1ec7t Nam, cho th\u1ea5y s\u1ee9c h\u1ea5p d\u1eabn c\u1ee7a \u0111\u1ea5t n\u01b0\u1edbc v\u1edbi t\u01b0 c\u00e1ch l\u00e0 c\u01a1 s\u1edf s\u1ea3n xu\u1ea5t v\u00e0 ti\u00eau d\u00f9ng.[15]<\/a>.<\/p>\n

Danh s\u00e1ch m\u1ed9t s\u1ed1 c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m ch\u00ednh t\u1ea1i Vi\u1ec7t Nam<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
STT<\/strong><\/td>\nC\u00f4ng ty<\/strong><\/td>\nN\u0103m th\u00e0nh l\u1eadp<\/strong><\/td>\nTr\u1ee5 s\u1edf ch\u00ednh<\/strong><\/td>\nQu\u00ea h\u01b0\u01a1ng<\/strong><\/td>\nH\u1ed3 s\u01a1 ng\u1eafn<\/strong><\/td>\nDoanh thu thu\u1ea7n 2023 (T\u1ef7 \u0111\u1ed3ng)<\/strong><\/td>\n<\/tr>\n
1<\/td>\nC\u00f4ng ty c\u1ed5 ph\u1ea7n d\u01b0\u1ee3c ph\u1ea9m DHG (DHG Pharma)<\/td>\n1974<\/td>\nC\u1ea7n Th\u01a1<\/td>\nVi\u1ec7t Nam<\/td>\nC\u00f3 th\u1ebf m\u1ea1nh trong c\u00e1c s\u1ea3n ph\u1ea9m thu\u1ed1c generic c\u00f3 th\u01b0\u01a1ng hi\u1ec7u, thu\u1ed1c kh\u00f4ng k\u00ea \u0111\u01a1n v\u00e0 th\u1ef1c ph\u1ea9m ch\u1ee9c n\u0103ng v\u1edbi m\u1ea1ng l\u01b0\u1edbi ph\u00e2n ph\u1ed1i to\u00e0n qu\u1ed1c.<\/td>\n5,768<\/td>\n<\/tr>\n
2<\/td>\nC\u00f4ng ty C\u1ed5 ph\u1ea7n Sanofi Vi\u1ec7t Nam<\/td>\n1950<\/td>\nH\u1ed3 Ch\u00ed Minh<\/td>\nPh\u00e1p<\/td>\nC\u00f4ng ty v\u1eadn h\u00e0nh nhi\u1ec1u nh\u00e0 m\u00e1y \u0111\u1ea1t ti\u00eau chu\u1ea9n WHO-GMP, s\u1edf h\u1eefu danh m\u1ee5c s\u1ea3n ph\u1ea9m \u0111a d\u1ea1ng bao g\u1ed3m thu\u1ed1c k\u00ea \u0111\u01a1n, s\u1ea3n ph\u1ea9m ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe ng\u01b0\u1eddi ti\u00eau d\u00f9ng v\u00e0 v\u1eafc-xin; g\u1ea7n \u0111\u00e2y \u0111\u00e3 \u0111\u1ea7u t\u01b0 v\u00e0o s\u1ea3n xu\u1ea5t v\u1eafc-xin trong n\u01b0\u1edbc.<\/td>\n3,734<\/td>\n<\/tr>\n
3<\/td>\nC\u00f4ng ty c\u1ed5 ph\u1ea7n Traphaco<\/td>\n1972<\/td>\nH\u00e0 N\u1ed9i<\/td>\nVi\u1ec7t Nam<\/td>\nNh\u00e0 s\u1ea3n xu\u1ea5t h\u00e0ng \u0111\u1ea7u c\u00e1c lo\u1ea1i thu\u1ed1c th\u1ea3o d\u01b0\u1ee3c v\u00e0 thu\u1ed1c hi\u1ec7n \u0111\u1ea1i; ti\u00ean phong trong chu\u1ed7i gi\u00e1 tr\u1ecb v\u00e0 nghi\u00ean c\u1ee9u ph\u00e1t tri\u1ec3n d\u01b0\u1ee3c li\u1ec7u c\u1ee7a GACP.<\/td>\n2,456<\/td>\n<\/tr>\n
4<\/td>\nC\u00f4ng ty TNHH Li\u00ean doanh Stellapharm<\/td>\n2000<\/td>\nB\u00ecnh D\u01b0\u01a1ng<\/td>\nVi\u1ec7t Nam<\/td>\nNh\u00e0 s\u1ea3n xu\u1ea5t thu\u1ed1c generic \u0111\u1ea1t chu\u1ea9n EU-GMP, m\u1ea1nh v\u1ec1 thu\u1ed1c tim m\u1ea1ch, thu\u1ed1c tr\u1ecb ti\u1ec3u \u0111\u01b0\u1eddng v\u00e0 thu\u1ed1c kh\u00e1ng virus, xu\u1ea5t kh\u1ea9u sang h\u01a1n 50 qu\u1ed1c gia.<\/td>\n2,329<\/td>\n<\/tr>\n
5<\/td>\nT\u1eadp \u0111o\u00e0n Imexpharm<\/td>\n1977<\/td>\n\u0110\u1ed3ng Th\u00e1p<\/td>\nVi\u1ec7t Nam<\/td>\nNh\u00e0 s\u1ea3n xu\u1ea5t thu\u1ed1c g\u1ed1c ch\u1ea5t l\u01b0\u1ee3ng cao; ti\u00ean phong \u00e1p d\u1ee5ng d\u00e2y chuy\u1ec1n s\u1ea3n xu\u1ea5t \u0111\u1ea1t ti\u00eau chu\u1ea9n EU-GMP v\u1edbi s\u1ef1 hi\u1ec7n di\u1ec7n m\u1ea1nh m\u1ebd t\u1ea1i c\u00e1c b\u1ec7nh vi\u1ec7n (ETC).<\/td>\n2,034<\/td>\n<\/tr>\n
6<\/td>\nC\u00f4ng ty D\u01b0\u1ee3c ph\u1ea9m Tenamyd<\/td>\n1950<\/td>\nH\u1ed3 Ch\u00ed Minh<\/td>\nVi\u1ec7t Nam<\/td>\nChuy\u00ean s\u1ea3n xu\u1ea5t d\u01b0\u1ee3c ph\u1ea9m, m\u1ef9 ph\u1ea9m, th\u1ef1c ph\u1ea9m ch\u1ee9c n\u0103ng, thi\u1ebft b\u1ecb b\u1ea3o h\u1ed9 y t\u1ebf, v.v.<\/td>\n2,021<\/td>\n<\/tr>\n
7<\/td>\nC\u00f4ng ty C\u1ed5 ph\u1ea7n D\u01b0\u1ee3c ph\u1ea9m Hatay<\/td>\n1965<\/td>\nH\u00e0 N\u1ed9i<\/td>\nVi\u1ec7t Nam<\/td>\nS\u1ea3n xu\u1ea5t v\u00e0 ph\u00e2n ph\u1ed1i d\u01b0\u1ee3c ph\u1ea9m t\u1ea1i Vi\u1ec7t Nam<\/td>\n1,916<\/td>\n<\/tr>\n
8<\/td>\nC\u00f4ng ty C\u1ed5 ph\u1ea7n Xu\u1ea5t Nh\u1eadp kh\u1ea9u Thi\u1ebft b\u1ecb Y t\u1ebf Domesco<\/td>\n1989<\/td>\n\u0110\u1ed3ng Th\u00e1p<\/td>\nVi\u1ec7t Nam<\/td>\nS\u1ea3n xu\u1ea5t d\u01b0\u1ee3c ph\u1ea9m, thu\u1ed1c th\u1ea3o d\u01b0\u1ee3c, th\u1ef1c ph\u1ea9m ch\u1ee9c n\u0103ng, n\u01b0\u1edbc u\u1ed1ng tinh khi\u1ebft v\u00e0 \u0111\u1ed3 u\u1ed1ng th\u1ea3o d\u01b0\u1ee3c\u2026<\/td>\n1,72<\/td>\n<\/tr>\n
9<\/td>\nC\u00f4ng ty C\u1ed5 ph\u1ea7n Pymepharco<\/td>\n1989<\/td>\nPh\u00fa Y\u00ean<\/td>\nVi\u1ec7t Nam<\/td>\nNh\u00e0 s\u1ea3n xu\u1ea5t thu\u1ed1c kh\u00e1ng sinh v\u00e0 thu\u1ed1c g\u1ed1c h\u00e0ng \u0111\u1ea7u; hi\u1ec7n \u0111ang xu\u1ea5t kh\u1ea9u c\u00e1c s\u1ea3n ph\u1ea9m \u0111\u1ea1t ti\u00eau chu\u1ea9n EU-GMP sang ch\u00e2u \u00c2u d\u01b0\u1edbi th\u01b0\u01a1ng hi\u1ec7u STADA.<\/td>\n1,582<\/td>\n<\/tr>\n
10<\/td>\nC\u00f4ng ty C\u1ed5 ph\u1ea7n D\u01b0\u1ee3c ph\u1ea9m v\u00e0 Thi\u1ebft b\u1ecb Y t\u1ebf B\u00ecnh \u0110\u1ecbnh (Bidiphar)<\/td>\n1980<\/td>\nQuy Nh\u01a1n<\/td>\nVi\u1ec7t Nam<\/td>\nNh\u00e0 s\u1ea3n xu\u1ea5t h\u00e0ng \u0111\u1ea7u v\u1edbi ph\u1ea1m vi ph\u1ee7 s\u00f3ng k\u00eanh ph\u00e2n ph\u1ed1i b\u1ec7nh vi\u1ec7n (ETC) m\u1ea1nh m\u1ebd v\u00e0 danh m\u1ee5c s\u1ea3n ph\u1ea9m chuy\u00ean v\u1ec1 ung th\u01b0.<\/td>\n1,582<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Ngu\u1ed3n: C\u01a1 s\u1edf d\u1eef li\u1ec7u v\u00e0 t\u1ed5ng h\u1ee3p doanh nghi\u1ec7p c\u1ee7a B&Company<\/em><\/p>\n

\u00dd ngh\u0129a \u0111\u1ed1i v\u1edbi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 n\u01b0\u1edbc ngo\u00e0i<\/strong><\/h3>\n

\u0110\u1ed1i v\u1edbi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 \u0111ang quan t\u00e2m \u0111\u1ebfn c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m t\u1ea1i Vi\u1ec7t Nam, m\u1ed9t s\u1ed1 y\u1ebfu t\u1ed1 th\u1ef1c ti\u1ec5n c\u1ea7n \u0111\u01b0\u1ee3c l\u01b0u \u00fd:<\/p>\n

Nh\u1eefng c\u01a1 h\u1ed9i<\/em><\/strong><\/h4>\n

Th\u1ecb tr\u01b0\u1eddng d\u01b0\u1ee3c ph\u1ea9m Vi\u1ec7t Nam hi\u1ec7n \u0111ang r\u1ea5t h\u1ea5p d\u1eabn, mang \u0111\u1ebfn nh\u1eefng c\u01a1 h\u1ed9i \u0111\u00e1ng k\u1ec3 \u0111\u01b0\u1ee3c th\u00fac \u0111\u1ea9y b\u1edfi ba y\u1ebfu t\u1ed1 ch\u00ednh. Th\u1ee9 nh\u1ea5t, th\u1ecb tr\u01b0\u1eddng h\u1ee9a h\u1eb9n t\u0103ng tr\u01b0\u1edfng cao v\u00e0 b\u1ec1n v\u1eefng; m\u1eb7c d\u00f9 gi\u00e1 tr\u1ecb hi\u1ec7n t\u1ea1i kh\u00e1 l\u1edbn, chi ti\u00eau b\u00ecnh qu\u00e2n \u0111\u1ea7u ng\u01b0\u1eddi th\u1ea5p cho th\u1ea5y ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng \u0111\u00e1ng k\u1ec3, \u0111\u1eb7c bi\u1ec7t l\u00e0 \u1edf c\u00e1c ph\u00e2n kh\u00fac tr\u1ecdng \u0111i\u1ec3m nh\u01b0 thu\u1ed1c g\u1ed1c, thu\u1ed1c chuy\u00ean khoa v\u00e0 v\u1eafc-xin. Th\u1ee9 hai, ti\u1ec1m n\u0103ng n\u00e0y \u0111\u01b0\u1ee3c c\u1ee7ng c\u1ed1 b\u1edfi ch\u00ednh s\u00e1ch th\u00e2n thi\u1ec7n v\u1edbi FDI, khi Lu\u1eadt D\u01b0\u1ee3c s\u1eeda \u0111\u1ed5i l\u00e0m r\u00f5 quy\u1ec1n c\u1ee7a c\u00e1c doanh nghi\u1ec7p c\u00f3 v\u1ed1n \u0111\u1ea7u t\u01b0 n\u01b0\u1edbc ngo\u00e0i (FIE) v\u00e0 t\u00ecm c\u00e1ch gi\u1ea3m b\u1edbt g\u00e1nh n\u1eb7ng h\u00e0nh ch\u00ednh, \u0111\u1eb7c bi\u1ec7t khuy\u1ebfn kh\u00edch s\u1ea3n xu\u1ea5t c\u00f4ng ngh\u1ec7 cao v\u00e0 chuy\u1ec3n giao c\u00f4ng ngh\u1ec7. Cu\u1ed1i c\u00f9ng, th\u1ecb tr\u01b0\u1eddng c\u00f3 nhi\u1ec1u ti\u1ec1m n\u0103ng h\u1ee3p t\u00e1c v\u00e0 mua b\u00e1n s\u00e1p nh\u1eadp; s\u1ef1 ph\u00e2n m\u1ea3nh hi\u1ec7n t\u1ea1i c\u1ee7a ng\u00e0nh v\u00e0 nhu c\u1ea7u v\u1ed1n c\u1ee7a c\u00e1c doanh nghi\u1ec7p trong n\u01b0\u1edbc t\u1ea1o ra nhi\u1ec1u d\u01b0 \u0111\u1ecba cho \u0111\u1ea7u t\u01b0 v\u1ed1n c\u1ed5 ph\u1ea7n v\u00e0o c\u00e1c doanh nghi\u1ec7p h\u00e0ng \u0111\u1ea7u trong n\u01b0\u1edbc (nh\u01b0 c\u00e1c nh\u00e0 s\u1ea3n xu\u1ea5t \u0111\u1ea1t ch\u1ee9ng nh\u1eadn EU-GMP) v\u00e0 thi\u1ebft l\u1eadp c\u00e1c li\u00ean minh chi\u1ebfn l\u01b0\u1ee3c trong c\u00e1c l\u0129nh v\u1ef1c nh\u01b0 nghi\u00ean c\u1ee9u v\u00e0 ph\u00e1t tri\u1ec3n, thu\u1ed1c g\u1ed1c c\u00f3 th\u01b0\u01a1ng hi\u1ec7u v\u00e0 s\u1ea3n xu\u1ea5t v\u1eafc-xin.<\/p>\n

Th\u00e1ch th\u1ee9c<\/em><\/strong><\/h4>\n

C\u00e1c c\u00f4ng ty ho\u1ea1t \u0111\u1ed9ng trong l\u0129nh v\u1ef1c d\u01b0\u1ee3c ph\u1ea9m t\u1ea1i Vi\u1ec7t Nam ph\u1ea3i \u0111\u1ed1i m\u1eb7t v\u1edbi m\u1ed9t s\u1ed1 th\u00e1ch th\u1ee9c c\u1ed1t l\u00f5i. H\u1ea1n ch\u1ebf ph\u00e2n ph\u1ed1i \u0111\u1ed1i v\u1edbi c\u00e1c doanh nghi\u1ec7p c\u00f3 v\u1ed1n \u0111\u1ea7u t\u01b0 n\u01b0\u1edbc ngo\u00e0i v\u1eabn l\u00e0 v\u1ea5n \u0111\u1ec1 nan gi\u1ea3i. C\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m n\u01b0\u1edbc ngo\u00e0i b\u1ecb c\u1ea5m ho\u1ea1t \u0111\u1ed9ng b\u00e1n bu\u00f4n v\u00e0 b\u00e1n l\u1ebb thu\u1ed1c th\u00e0nh ph\u1ea9m, bu\u1ed9c ph\u1ea3i ph\u1ee5 thu\u1ed9c v\u00e0o c\u00e1c nh\u00e0 ph\u00e2n ph\u1ed1i trong n\u01b0\u1edbc, \u0111i\u1ec1u n\u00e0y th\u01b0\u1eddng l\u00e0m gi\u1ea3m l\u1ee3i nhu\u1eadn. Tuy nhi\u00ean, Lu\u1eadt D\u01b0\u1ee3c s\u1eeda \u0111\u1ed5i (2024) l\u00e0m r\u00f5 r\u1eb1ng c\u00e1c doanh nghi\u1ec7p c\u00f3 c\u01a1 s\u1edf s\u1ea3n xu\u1ea5t trong n\u01b0\u1edbc hi\u1ec7n \u0111\u01b0\u1ee3c ph\u00e9p th\u1ef1c hi\u1ec7n m\u1ed9t s\u1ed1 ho\u1ea1t \u0111\u1ed9ng h\u1eadu c\u1ea7n\/gia t\u0103ng gi\u00e1 tr\u1ecb n\u1ed9i b\u1ed9 (v\u00ed d\u1ee5: l\u01b0u tr\u1eef, ki\u1ec3m so\u00e1t ch\u1ea5t l\u01b0\u1ee3ng, v\u1eadn chuy\u1ec3n n\u1ed9i \u0111\u1ecba) cho s\u1ea3n ph\u1ea9m c\u1ee7a m\u00ecnh, mang l\u1ea1i s\u1ef1 thu\u1eadn l\u1ee3i h\u01a1n m\u1ed9t ch\u00fat v\u1ec1 m\u1eb7t ho\u1ea1t \u0111\u1ed9ng m\u00e0 kh\u00f4ng l\u00e0m thay \u0111\u1ed5i l\u1ec7nh c\u1ea5m ph\u00e2n ph\u1ed1i c\u1ed1t l\u00f5i. H\u01a1n n\u1eefa, m\u00f4i tr\u01b0\u1eddng kinh doanh c\u00f2n ph\u1ee9c t\u1ea1p v\u1edbi ch\u00ednh s\u00e1ch gi\u00e1 c\u1ea3 v\u00e0 ho\u00e0n tr\u1ea3 chi ph\u00ed. C\u00e1c quy \u0111\u1ecbnh nghi\u00eam ng\u1eb7t v\u1ec1 khai b\u00e1o gi\u00e1 v\u00e0 ch\u00ednh s\u00e1ch ho\u00e0n tr\u1ea3 chi ph\u00ed li\u00ean t\u1ee5c thay \u0111\u1ed5i \u0111\u00f2i h\u1ecfi c\u00e1c c\u00f4ng ty ph\u1ea3i c\u00f3 kh\u1ea3 n\u0103ng ti\u1ebfp c\u1eadn th\u1ecb tr\u01b0\u1eddng m\u1ea1nh m\u1ebd v\u00e0 n\u0103ng l\u1ef1c kinh t\u1ebf y t\u1ebf v\u1eefng ch\u1eafc \u0111\u1ec3 qu\u1ea3n l\u00fd s\u1ea3n ph\u1ea9m hi\u1ec7u qu\u1ea3. Cu\u1ed1i c\u00f9ng, ng\u00e0nh n\u00e0y tr\u1ea3i qua s\u1ef1 c\u1ea1nh tranh gi\u00e1 c\u1ea3 gay g\u1eaft trong m\u1ed9t th\u1ecb tr\u01b0\u1eddng ph\u00e2n m\u1ea3nh cao. V\u1edbi h\u00e0ng tr\u0103m nh\u00e0 s\u1ea3n xu\u1ea5t c\u1ea1nh tranh kh\u1ed1c li\u1ec7t, \u0111\u1eb7c bi\u1ec7t l\u00e0 trong ph\u00e2n kh\u00fac thu\u1ed1c generic, \u00e1p l\u1ef1c v\u1ec1 gi\u00e1 l\u00e0 v\u00f4 c\u00f9ng cao. Do \u0111\u00f3, th\u00e0nh c\u00f4ng ph\u1ee5 thu\u1ed9c v\u00e0o kh\u1ea3 n\u0103ng c\u1ee7a m\u1ed9t c\u00f4ng ty trong vi\u1ec7c t\u1ea1o s\u1ef1 kh\u00e1c bi\u1ec7t th\u00f4ng qua ch\u1ea5t l\u01b0\u1ee3ng v\u01b0\u1ee3t tr\u1ed9i, tu\u00e2n th\u1ee7 quy \u0111\u1ecbnh, x\u00e2y d\u1ef1ng th\u01b0\u01a1ng hi\u1ec7u v\u00e0 d\u1ecbch v\u1ee5.<\/p>\n

\u00a0<\/em><\/p>\n

* L\u01b0u \u00fd: N\u1ebfu b\u1ea1n mu\u1ed1n tr\u00edch d\u1eabn th\u00f4ng tin trong b\u00e0i vi\u1ebft n\u00e0y, vui l\u00f2ng ghi r\u00f5 ngu\u1ed3n v\u00e0 k\u00e8m theo link b\u00e0i vi\u1ebft \u0111\u1ec3 \u0111\u1ea3m b\u1ea3o t\u00f4n tr\u1ecdng b\u1ea3n quy\u1ec1n.<\/em><\/p>\n\n\n\n
B&Company, Inc.<\/em><\/strong><\/p>\n

C\u00f4ng ty nghi\u00ean c\u1ee9u th\u1ecb tr\u01b0\u1eddng c\u1ee7a Nh\u1eadt B\u1ea3n \u0111\u1ea7u ti\u00ean t\u1ea1i Vi\u1ec7t Nam t\u1eeb n\u0103m 2008. Ch\u00fang t\u00f4i cung c\u1ea5p \u0111a d\u1ea1ng nh\u1eefng d\u1ecbch v\u1ee5 bao g\u1ed3m b\u00e1o c\u00e1o ng\u00e0nh, ph\u1ecfng v\u1ea5n ng\u00e0nh, kh\u1ea3o s\u00e1t ng\u01b0\u1eddi ti\u00eau d\u00f9ng, k\u1ebft n\u1ed1i kinh doanh. Ngo\u00e0i ra, ch\u00fang t\u00f4i \u0111\u00e3 ph\u00e1t tri\u1ec3n c\u01a1 s\u1edf d\u1eef li\u1ec7u c\u1ee7a h\u01a1n 900,000 c\u00f4ng ty t\u1ea1i Vi\u1ec7t Nam, c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng \u0111\u1ec3 t\u00ecm ki\u1ebfm \u0111\u1ed1i t\u00e1c kinh doanh v\u00e0 ph\u00e2n t\u00edch th\u1ecb tr\u01b0\u1eddng.<\/p>\n

Xin vui l\u00f2ng li\u00ean h\u1ec7 v\u1edbi ch\u00fang t\u00f4i n\u1ebfu b\u1ea1n c\u00f3 b\u1ea5t k\u1ef3 th\u1eafc m\u1eafc hay nhu c\u1ea7u n\u00e0o.<\/p>\n

info@b-company.jp<\/em><\/a>\u00a0+ (84) 28 3910 3913<\/strong><\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

[1]<\/a> https:\/\/www.trade.gov\/market-intelligence\/vietnam-pharmaceutical-industry-updates<\/p>\n

[2]<\/a> https:\/\/vneconomy.vn\/thi-truong-thuoc-generic-viet-nam-co-hoi-55-ty-usd-va-rao-can-tu-tieu-chuan-chat-luong.htm<\/p>\n

[3]<\/a> https:\/\/ven.congthuong.vn\/vietnam-forecast-to-spearhead-asean-generic-drug-market-expansion-58234.html<\/p>\n

[4]<\/a> https:\/\/assets.kpmg.com\/content\/dam\/kpmg\/vn\/pdf\/2025\/10\/future-value-of-vietnam-generics-market-eng.pdf<\/p>\n

[5]<\/a> https:\/\/mekongasean.vn\/duoc-pham-la-mat-hang-viet-nam-nhap-khau-lon-nhat-tu-phap-33909.html<\/p>\n

[6]<\/a> https:\/\/vir.com.vn\/pharma-to-experience-robust-growth-114808.html<\/p>\n

[7]<\/a> https:\/\/www.statista.com\/statistics\/1116617\/vietnam-market-share-of-imported-and-domestic-pharmaceuticals\/<\/p>\n

[8]<\/a> https:\/\/doanhnghiephoinhap.vn\/giua-con-bao-quet-thuoc-gia-nhin-lai-cuoc-dua-cua-3-chuoi-duoc-pham-long-chau-pharmacity-va-an-khang-107314.html&link=autochanger<\/p>\n

[9]<\/a> https:\/\/vneconomy.vn\/dan-dau-ve-so-luong-nha-thuoc-1-796-tren-toan-quoc-tong-doanh-thu-32-000-ty-con-rui-ro-nao-ma-frt-phai-luu-y.htm<\/p>\n

[10]<\/a> https:\/\/kirincapital.vn\/wp-content\/uploads\/2023\/11\/Bao-cao-nganh-duoc-pham-VN.pdf<\/p>\n

[11]<\/a> https:\/\/vietnamnews.vn\/economy\/1718551\/viet-nam-s-pharmaceutical-market-sees-major-m-a-deal.html<\/p>\n

[12]<\/a> https:\/\/vir.com.vn\/south-korean-dongwha-pharm-buys-majority-stake-in-vietnams-trung-son-pharma-104172.html&link=autochanger<\/p>\n

[13]<\/a> https:\/\/tuoitre.vn\/hang-duoc-trung-quoc-du-chi-hon-5-700-ti-dong-de-mua-gan-65-von-imexpharm-20250523015415335.htm<\/p>\n

[14]<\/a> https:\/\/thesaigontimes.vn\/nganh-duoc-nang-cap-tieu-chuan-tim-duong-ra-the-gioi\/<\/p>\n

[15]<\/a> https:\/\/assets.kpmg.com\/content\/dam\/kpmg\/vn\/pdf\/2025\/10\/future-value-of-vietnam-generics-market-eng.pdf<\/p>","protected":false},"excerpt":{"rendered":"

C\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m t\u1ea1i Vi\u1ec7t Nam ho\u1ea1t \u0111\u1ed9ng trong m\u1ed9t m\u00f4i tr\u01b0\u1eddng \u0111\u01b0\u1ee3c qu\u1ea3n l\u00fd ch\u1eb7t ch\u1ebd nh\u01b0ng \u0111ang d\u1ea7n \u0111\u01b0\u1ee3c t\u1ef1 do h\u00f3a, khuy\u1ebfn kh\u00edch \u0111\u1ea7u t\u01b0.<\/p>","protected":false},"author":12,"featured_media":23153,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1357,85],"tags":[1204],"yoast_head":"\nPharmaceutical market in Vietnam: Landscape, key players and regulatory overview - B-Company<\/title>\n<meta name=\"description\" content=\"Pharmaceutical companies in Vietnam operate in a highly regulated but gradually liberalizing environment that encourages investment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/b-company.jp\/vi\/pharmaceutical-market-in-vietnam-landscape-key-players-and-regulatory-overview\/\" \/>\n<meta property=\"og:locale\" content=\"vi_VN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmaceutical market in Vietnam: Landscape, key players and regulatory overview - B-Company\" \/>\n<meta property=\"og:description\" content=\"Pharmaceutical companies in Vietnam operate in a highly regulated but gradually liberalizing environment that encourages investment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/b-company.jp\/vi\/pharmaceutical-market-in-vietnam-landscape-key-players-and-regulatory-overview\/\" \/>\n<meta property=\"og:site_name\" content=\"B-Company\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-11T02:25:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/b-company.jp\/wp-content\/uploads\/2025\/12\/Pharmaceutical-Market-in-Vietnam.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/b-company.jp\/vi\/#website\",\"url\":\"https:\/\/b-company.jp\/vi\/\",\"name\":\"B-Company\",\"description\":\"Vietnam Market Research & Investment Consulting\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/b-company.jp\/vi\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"vi\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/b-company.jp\/pharmaceutical-market-in-vietnam-landscape-key-players-and-regulatory-overview\/#primaryimage\",\"inLanguage\":\"vi\",\"url\":\"https:\/\/b-company.jp\/wp-content\/uploads\/2025\/12\/Pharmaceutical-Market-in-Vietnam.jpg\",\"width\":1920,\"height\":1280,\"caption\":\"Pharmaceutical Market in Vietnam\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/b-company.jp\/pharmaceutical-market-in-vietnam-landscape-key-players-and-regulatory-overview\/#webpage\",\"url\":\"https:\/\/b-company.jp\/pharmaceutical-market-in-vietnam-landscape-key-players-and-regulatory-overview\/\",\"name\":\"Pharmaceutical market in Vietnam: Landscape, key players and regulatory overview - B-Company\",\"isPartOf\":{\"@id\":\"https:\/\/b-company.jp\/vi\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/b-company.jp\/pharmaceutical-market-in-vietnam-landscape-key-players-and-regulatory-overview\/#primaryimage\"},\"datePublished\":\"2025-12-11T02:25:34+00:00\",\"dateModified\":\"2025-12-11T02:25:34+00:00\",\"author\":{\"@id\":\"https:\/\/b-company.jp\/vi\/#\/schema\/person\/5e219c48d2d517d136e89dbb96bd0491\"},\"description\":\"Pharmaceutical companies in Vietnam operate in a highly regulated but gradually liberalizing environment that encourages investment.\",\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/b-company.jp\/pharmaceutical-market-in-vietnam-landscape-key-players-and-regulatory-overview\/\"]}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/b-company.jp\/vi\/#\/schema\/person\/5e219c48d2d517d136e89dbb96bd0491\",\"name\":\"B& Company\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/b-company.jp\/vi\/#personlogo\",\"inLanguage\":\"vi\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0d1ba67df903c626f39b0344b14b25e4?s=96&d=mm&r=g\",\"caption\":\"B& Company\"},\"sameAs\":[\"http:\/\/b-company.jp\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","_links":{"self":[{"href":"https:\/\/b-company.jp\/vi\/wp-json\/wp\/v2\/posts\/23150"}],"collection":[{"href":"https:\/\/b-company.jp\/vi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/b-company.jp\/vi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/b-company.jp\/vi\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/b-company.jp\/vi\/wp-json\/wp\/v2\/comments?post=23150"}],"version-history":[{"count":4,"href":"https:\/\/b-company.jp\/vi\/wp-json\/wp\/v2\/posts\/23150\/revisions"}],"predecessor-version":[{"id":23159,"href":"https:\/\/b-company.jp\/vi\/wp-json\/wp\/v2\/posts\/23150\/revisions\/23159"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/b-company.jp\/vi\/wp-json\/wp\/v2\/media\/23153"}],"wp:attachment":[{"href":"https:\/\/b-company.jp\/vi\/wp-json\/wp\/v2\/media?parent=23150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/b-company.jp\/vi\/wp-json\/wp\/v2\/categories?post=23150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/b-company.jp\/vi\/wp-json\/wp\/v2\/tags?post=23150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}